Trypsin + Chymotrypsin (Trypsinum + Chymotrypsinum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Enzymes and antiferments

Included in the formulation
  • Hymopsin®
    lyophilizate locally externally 
    SAMSON-MED, LLC     Russia
    • АТХ:

    B.06.A.A.07   Trypsin

    B.06.A.A.04   Chymotrypsin

    Pharmacodynamics:

    Combined enzyme preparation obtained from the pancreas of cattle. It has a proteolytic, anti-inflammatory, anti-edematous effect. Splits dead tissue sites, fibrin formation, viscous secrets, exudates. Inactive in relation to healthy tissues. Has no effect on hemostasis.

    Pharmacokinetics:

    Not studied.

    Indications:
    • Bronchoectatic disease, lung abscesses, exudative pleurisy, postoperative atelectasis, empyema of the pleura.
    • Treatment of purulent wounds and burns.
    • Chronic purulent otitis, purulent sinusitis, sinusitis.
    • Acute thrombophlebitis.
    • Acute and chronic odontogenic osteomyelitis.
    • Inflammatory-dystrophic forms of periodontitis.
    • Acute iridium and iridocyclitis, hemorrhages in the eye chamber and swelling of the periocular tissues after traumas and surgeries, obstruction of the tear ducts.
    • Burns.
    • Wounds covered with a thick scab.
    ICD-10

    VII.H15-H22.H20.0   Acute and subacute iridocyclitis

    VII.H15-H22.H20.1   Chronic iridocyclitis

    VII.H15-H22.H21.0   Hyphema

    VIII.H65-H75.H66.4   Purulent otitis media, unspecified

    IX.I80-I89.I80   Phlebitis and thrombophlebitis

    X.J00-J06.J01   Acute Sinusitis

    X.J30-J39.J32   Chronic Sinusitis

    X.J40-J47.J47   Bronchoectasia

    X.J85-J86.J85   Abscess of the lung and mediastinum

    X.J85-J86.J86   Pythothrace

    X.J90-J94.J91 *   Pleural effusion in conditions classified elsewhere

    XI.K00-K14.K05   Gingivitis and periodontal disease

    XI.K00-K14.K12   Stomatitis and related lesions

    XIII.M86-M90.M86   Osteomyelitis

    XIX.S00-S09.S05   Injury of the eye and orbit

    XIX.T20-T32.T30   Thermal and chemical burns, unspecified

    XIX.T08-T14.T14.1   Open wound of unspecified area of ​​the body

    XXI.Z20-Z29.Z29.8   Other specified preventive measures

    Contraindications:

    Hypersensitivity, decompensated chronic heart failure, pulmonary emphysema with respiratory failure, decompensated forms of pulmonary tuberculosis, liver dystrophy, liver cirrhosis, pancreatitis, infectious hepatitis, hemorrhagic vasculitis.

    Carefully:

    Empyema pleura tuberculosis etiology (resorption of exudate can contribute to the development of bronchopleural fistula).

    Pregnancy and lactation:

    Adequate and well-controlled studies in humans and animals have not been conducted. Carefully! There is no information on the penetration into breast milk. Carefully!

    Category of recommendations for FDA is not defined.

    Dosing and Administration:

    Intramuscularly 5-10 mg 1-2 times a day. For injections, dilute 5 mg of crystalline trypsin in 1-2 ml of a 0.9% sodium chloride solution or 0.5-2% procaine solution immediately before use. The course of treatment is 6-15 injections. Electrophoresis with trypsin: for 1 procedure 10 mg of trypsin (dissolve in 15-20 ml of distilled water), enter from the cathode.

    Inhalation: 5-10 mg in 2-3 ml of a 0.9% solution of sodium chloride through an inhaler or bronchoscope. After inhalation, rinse mouth with warm water and rinse nose.

    Eye drops: 0.2-0.25% solution, prepare ex tempore.

    Intrapleural: once a day 10-20 mg, dissolving in 20-50 ml of 0.9% solution of sodium chloride.

    Locally in the form of a powder or amorphous trypsin solution, apply compresses on dry or necrotic wounds (ex tempore: 50 mg of trypsin dissolved in 5 ml of sterile water or 0.9% solution of sodium chloride, in the treatment of purulent wounds - in 5 ml of phosphate buffer solution).

    Side effects:

    Allergic reactions.

    Increased body temperature, tachycardia.

    Soreness and hyperemia at the injection site with intramuscular injection.

    When inhaling trypsin, irritation of the mucous membranes of the upper respiratory tract and hoarseness of the voice may appear.

    Overdose:

    Increased side effects.

    Treatment is symptomatic.

    Interaction:

    Not described.

    Special instructions:

    In the next few hours after inhalation, the patient should carefully cough up phlegm or it should be removed by sucking. Do not inject into bleeding cavities, do not apply to ulcerated surfaces of malignant tumors.

    Instructions
    Up